Amarin Corporation Plc Sponsored ADR Stock

$0.50

3.85% yesterday

Nasdaq, Nov 15, 10:00 pm CET

ISIN

US0231112063

Symbol

AMRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Amarin Corporation Plc Sponsored ADR Stock price

$0.50

-23.52 97.92% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.02 3.85%

ISIN

US0231112063

Symbol

AMRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$205.63m
Enterprise Value	$-92.41m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	5.01
EV/Sales (TTM) EV/Sales	-0.38
P/S ratio (TTM) P/S ratio	0.85
P/B ratio (TTM) P/B ratio	0.39
Revenue growth (TTM) Revenue growth	-25.21%
Revenue (TTM) Revenue	$242.15m
EBIT (operating result TTM) EBIT	$-44.17m
Free Cash Flow (TTM) Free Cash Flow	$-18.44m
Cash position	$306.26m
EPS (TTM) EPS	$-0.10
P/E forward	negative
P/S forward	1.03
EV/Sales forward	negative
Short interest	4.42%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Amarin Corporation Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

1x Hold

33%

2x Sell

67%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

Hold

33%

Sell

67%

Analyst Estimates with Stock Price Targets

Financial data from Amarin Corporation Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	242 242	25% 25% 100%
- Direct Costs	109 109	24% 24% 45%
Gross Profit	134 134	27% 27% 55%
- Selling and Administrative Expenses	157 157	29% 29% 65%
- Research and Development Expense	18 18	5% 5% 7%
EBITDA	-41 -41	30% 30% -17%
- Depreciation and Amortization	3.02 3.02	1% 1% 1%
EBIT (Operating Income) EBIT	-44 -44	29% 29% -18%
Net Profit	-40 -40	25% 25% -16%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Amarin Corporation Plc Sponsored ADR Stock News

Neutral

Seeking Alpha

●

16 days ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conf...

Neutral

GlobeNewsWire

●

2 months ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th An...

Neutral

GlobeNewsWire

●

3 months ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European S...

More Amarin Corporation Plc Sponsored ADR News

Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Head office	United Kingdom
CEO	Aaron Berg
Employees	275
Founded	1989
Website	www.amarincorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now